Latest Articles
Pain Scores Drop from 8/10 to Zero: IceCure's ProSense Shows Breakthrough Results in Endometriosis Treatment - Stock Titan
Pain Scores Drop from 8/10 to Zero: IceCure's ProSense Shows Breakthrough Results in Endometriosis Treatment Stock Titan
Published: Sept. 4, 2025, 12:30 p.m.
Genmab shares rise 1.21% premarket after FDA grants Breakthrough Therapy Designation to Rina-S for endometrial cancer treatment. - AInvest
Genmab shares rise 1.21% premarket after FDA grants Breakthrough Therapy Designation to Rina-S for endometrial cancer treatment. AInvest
Published: Aug. 28, 2025, 8:24 a.m.
Breakthrough designation for Genmab’s Rina-S in USA - The Pharma Letter
Breakthrough designation for Genmab’s Rina-S in USA The Pharma Letter
Published: Aug. 27, 2025, 6:11 p.m.
Elucidation of the mechanism of treating endometriosis with Ge Xia-Zhu Yu decoction by means of network pharmacology and molecular docking.
This study investigates the mechanism of Ge Xia-Zhu Yu decoction (GXZYT) in the treatment of endometriosis (EMS). The active components and targets of GXZYT were screened using TCMSP database and …
Published: Aug. 27, 2025, midnight
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer - CancerNetwork
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer CancerNetwork
Published: Aug. 26, 2025, 10:07 p.m.
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer - Targeted Oncology
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer Targeted Oncology
Published: Aug. 26, 2025, 6:30 p.m.
Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer - Oncology Nursing News
Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer Oncology Nursing News
Published: Aug. 26, 2025, 6:04 p.m.
Genmab's Rina-S: A Breakthrough in Endometrial Cancer and a Catalyst for Shareholder Value - AInvest
Genmab's Rina-S: A Breakthrough in Endometrial Cancer and a Catalyst for Shareholder Value AInvest
Published: Aug. 26, 2025, 5:39 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced - PharmiWeb.com
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced PharmiWeb.com
Published: Aug. 26, 2025, 4:10 p.m.
Rina-S Earns Breakthrough Designation in Advanced Endometrial Cancer - Curetoday
Rina-S Earns Breakthrough Designation in Advanced Endometrial Cancer Curetoday
Published: Aug. 26, 2025, 4:06 p.m.
Link copied to clipboard!